{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:01:04Z","timestamp":1793228464934,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016279","name":"Harris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.020","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:16:01Z","timestamp":1785698161000},"page":"739-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Universally offered germline testing in upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Jesse TR","family":"Spooner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Igel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig V.","family":"Labbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donika","family":"Saporito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Vilar-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrad","family":"Adibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-1445","authenticated-orcid":false,"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.020_bib0001","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/sj.ejhg.5201584","article-title":"Phenotypic and genotypic heterogeneity in the lynch syndrome: diagnostic, surveillance and management implications","volume":"14","author":"Lynch","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0003","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013High advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0004","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013Deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1147591","article-title":"Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors","volume":"13","author":"Rasmussen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0006","first-page":"4749","article-title":"Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression","volume":"57","author":"Dietmaier","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0007","first-page":"290","article-title":"Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry","author":"Yang","year":"2025","journal-title":"Cancer Genet"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2017.08.002","article-title":"Universal point of care testing for Lynch syndrome in patients with upper tract urothelial carcinoma","volume":"199","author":"Metcalfe","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djad016","article-title":"Comprehensive analysis of germline drivers in endometrial cancer","volume":"115","author":"Gordhandas","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0011","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/j.cgh.2021.04.013","article-title":"Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study","volume":"20","author":"Uson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2026.110999","article-title":"Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"44","author":"Moryousef","year":"2026","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0013","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0014","article-title":"Inherited germline variants in urinary tract cancer: a multicenter whole-exome sequencing analysis and correlation with clinical features and tumor genomics","volume":"8","author":"Kohlmann","year":"2024","journal-title":"J Precis Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0016","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0017","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG\u2013AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0018","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JU.0000000000004089","article-title":"Germline pathogenic variants identified in patients with genitourinary malignancies undergoing universal testing: a multisite single-institution prospective study","volume":"212","author":"Choudry","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0019","series-title":"NCCN clinical practice guidelines in oncology: genetic\/familial high-risk assessment: colorectal, endometrial, and gastric, version 1.2025","year":"2025"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","article-title":"New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC","volume":"116","author":"Vasen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0021","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2016.69.6120","article-title":"Development and validation of the PREMM5 model for Comprehensive risk assessment of Lynch Syndrome","volume":"35","author":"Kastrinos","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ajg.2014.435","article-title":"ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes","volume":"110","author":"Syngal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2022.10.024","article-title":"Molecular testing for endometrial cancer: an SGO clinical practice statement","volume":"168","author":"Walsh","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0024","article-title":"Genotype-phenotype characterization of Lynch Syndrome\u2013associated upper tract urothelial carcinoma","author":"Labbate","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0025","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_mmr carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database","volume":"67","author":"M\u00f8ller","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116098","article-title":"Cancer risks for MSH6 pathogenic variant carriers","volume":"231","author":"Werf-\u2019t Lam","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0027","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00345-023-04344-9","article-title":"Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome","volume":"41","author":"Cerrato","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0028","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jmg.2010.077677","article-title":"Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers","volume":"47","author":"Sjursen","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0029","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.urology.2022.02.006","article-title":"Immunohistochemical screening of upper tract urothelial carcinomas for Lynch Syndrome diagnostics: a systematic review","volume":"165","author":"Rasmussen","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0031","article-title":"Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis","volume":"3","author":"Chandran","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0032","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.humpath.2020.07.001","article-title":"Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome","volume":"103","author":"Chen","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.818","article-title":"Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI)","volume":"43","author":"Moussa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/21501327211046734","article-title":"Genetic referral patterns and responses to clinical scenarios: a survey of primary care providers and clinical geneticists","volume":"12","author":"Truong","year":"2021","journal-title":"J Prim Care Community Health"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102220","article-title":"Survival outcomes by race following surgical treatment for upper tract urothelial carcinoma","volume":"22","author":"Zappia","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.07.020_bib0036","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate, Version 2.2026. National Comprehensive Cancer Network; n.d."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926006137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:25:58Z","timestamp":1790281558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926006137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926006137"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universally offered germline testing in upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}